Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Angiogenesis & Anti-VEGF

Francesco Bertolini

弗朗切斯科·贝尔托利尼

MD, PhD

🏢IEO – Istituto Europeo di Oncologia (European Institute of Oncology)(欧洲肿瘤研究所)🌐Italy

Head, Laboratory of Hematology-Oncology and Vascular Biology血液肿瘤学与血管生物学实验室主任

68
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Francesco Bertolini pioneered the use of circulating endothelial cells (CECs) as non-invasive biomarkers of tumor angiogenesis and antiangiogenic therapy response. He also played a foundational role in establishing metronomic chemotherapy as an antiangiogenic strategy, changing how low-dose continuous chemotherapy is conceptualized.

Share:

🧪Research Fields 研究领域

Circulating Endothelial Cells循环内皮细胞
Tumor Angiogenesis Biomarkers肿瘤血管生成生物标志物
Metronomic Chemotherapy节拍化疗
Anti-Angiogenic Therapy Monitoring抗血管生成治疗监测
Hematological Malignancies Vasculature血液恶性肿瘤血管系统

🎓Key Contributions 主要贡献

Circulating Endothelial Cells as Angiogenesis Biomarkers

Developed methods to quantify and characterize CECs from peripheral blood, establishing them as pharmacodynamic markers of antiangiogenic therapy and tumor vascularity in clinical trials.

Metronomic Chemotherapy and Angiogenesis

Demonstrated that low-dose metronomic chemotherapy suppresses tumor angiogenesis via endothelial cell targeting and Treg depletion, providing mechanistic rationale for this cost-effective antiangiogenic strategy.

Representative Works 代表性著作

[1]

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells

Cancer Research (2003)

Landmark study showing metronomic and maximum-tolerable-dose chemotherapy differ fundamentally in their effects on circulating endothelial progenitors and tumor angiogenesis.

[2]

Circulating endothelial cells as a novel marker of angiogenesis

Journal of Clinical Oncology (2006)

Established clinical validation of circulating endothelial cells as a surrogate marker of angiogenic activity and bevacizumab pharmacodynamics in cancer patients.

🏆Awards & Recognition 奖项与荣誉

🏆Italian Association for Cancer Research (AIRC) Investigator Grant
🏆European Research Council (ERC) Grant Recipient
🏆IEO Distinguished Researcher Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 弗朗切斯科·贝尔托利尼 的研究动态

Follow Francesco Bertolini's research updates

留下邮箱,当我们发布与 Francesco Bertolini(IEO – Istituto Europeo di Oncologia (European Institute of Oncology))相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment